This week we explore the dual impact of cannabis legalisation and rescheduling—focusing on both the massive financial implications for the industry and emerging scientific research on health benefits.

The $2 Billion Tax Windfall The program leads with a deep dive into the potential rescheduling of cannabis from Schedule I to Schedule III under the Controlled Substances Act. Experts estimate that rescheduling could result in a $2.3 billion tax break, allowing businesses to finally show healthy profit margins, attract traditional investors, and move away from high-risk private capital.

Cannabis as a Tool in the Opioid Crisis The discussion then shifts to a significant study from the Boston University School of Public Health. Research indicates that in states where adult-use cannabis is legal, daily opioid use among people who inject drugs fell by 9 to 11 percentage points.

Brain Benefits for Older Adults Finally, the episode highlights surprising new research from the University of Colorado regarding cannabis use in adults over 40. Contrary to long-standing stereotypes of cognitive decline, the study of over 26,000 participants found that moderate cannabis use—often for sleep or chronic pain—was associated with larger brain volumes in certain regions and better cognitive function (including improved processing speed and attention).

Advertising Inquiries: https://redcircle.com/brands

Privacy & Opt-Out: https://redcircle.com/privacy